Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ACT: Nerandomilast in Fibrosing Interstitial Lung Disease at Risk for Progression
jRCT2030260406Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in pulmonary fibrosis (PF) comparing Nerandomilast with Placebo (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 52. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on jRCT2030260406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2030260406.